Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | PTGES | O14684 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541175 | 0.89 | CYP1A2 (0.49) | HPGDHSD11B1PTGESPOLBCA12 | |
| SCHEMBL6541763 | 0.89 | HSD11B1 (0.47) | HPGDHSD11B1PTGESPOLB | |
| SCHEMBL6542420 | 0.82 | HSD11B1 (0.46) | HPGDHSD11B1PTGESPOLB | |
| SCHEMBL6541798 | 0.81 | HSD11B1 (0.46) | HPGDHSD11B1POLBCA12CA1 | |
| SCHEMBL6542493 | 0.79 | LMNA (0.56) | HPGDHSD11B1POLB | |
| SCHEMBL6542552 | 0.79 | HSD11B1 (0.47) | HPGDHSD11B1 | |
| SCHEMBL6542499 | 0.79 | HSD11B1 (0.47) | HPGDHSD11B1 | |
| SCHEMBL6542633 | 0.78 | EDNRA (0.48) | HPGDPOLB | |
| SCHEMBL6542462 | 0.78 | HSD11B1 (0.46) | HPGDHSD11B1 | |
| SCHEMBL6542604 | 0.77 | HSD11B1 (0.46) | HPGDHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1009743-B1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER LAMBERT CO (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20030073684-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2003-04-17 | — | — | US | disclosed |
| US-6545150-B2 | Preparing 1,1-dioxo-2-phenyl-3-carboxy-4-phenyl-1,2-benzo(e)-thiazines by a five-step process starting with a (2-(methyl-oxycarbonyl-)phenyl-sulfonamido-)benzene; alkylation; cyclization; hydroxylation; esterification and coupling | WARNER-LAMBERT COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6440962-B2 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS | WARNER-LAMBERT COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20020094980-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2002-07-18 | — | — | US | disclosed |
| US-6265399-B1 | ALKYLATION; CYCLIZATION | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6252070-B1 | REACTING ARYL BROMIDE WITH BUTYLLITHIUM AND ZINC BROMIDE TO GIVE ARYL ZINC BROMIDE; REACTING WITH CORRESPONDING BENZOTHIAZINE COMPOUND | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094980-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | HPGD 1103/4885HSD11B1 1320/4885PTGES 399/4885 |
| US-20030073684-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | HPGD 1103/4885HSD11B1 1320/4885PTGES 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.